We are live on ! Find out more
GS

Gilead Sciences Portfolio holdings

AUM $2.12B
1-Year Est. Return 143.53%
This Fund
S&P 500
This Quarter Est. Return
-20.18%
1 Year Est. Return
+143.53%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$1.18B
AUM Growth
-$370M
Cap. Flow
+$13.5M
Cap. Flow %
1.14%
Top 10 Hldgs %
99.56%
Holding
16
New
–
Increased
1
Reduced
2
Closed
2

Top Buys

Rank Stock Value
1
RCUS icon
Arcus Biosciences
RCUS
+$15.8M

Top Sells

Rank Stock Value
1
IMA
ImageneBio Inc
IMA
+$1.22M
2
AGEN
Agenus
AGEN
+$635K
3
BRNS
Barinthus Biotherapeutics
BRNS
+$257K
4
KRON
Kronos Bio
KRON
+$179K

Sector Composition

Rank Sector Weight
1 Healthcare 99.86%
2 Financials 0.14%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ACLX
1
DELISTED
Arcellx
ACLX
$441M 37.32%
6,720,803
– –
LKFT
2
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.78B
$419M 35.5%
16,707,477
– –
RCUS icon
3
Arcus Biosciences
RCUS
$3.55B
$247M 20.88%
31,424,760
+1,363,636
+5% +$15.8M
ASMB icon
4
Assembly Biosciences
ASMB
$498M
$21.1M 1.79%
2,209,471
– –
MRUS
5
DELISTED
Merus
MRUS
$19M 1.61%
452,527
– –
KYTX icon
6
Kyverna Therapeutics
KYTX
$444M
$7.96M 0.67%
4,126,119
– –
TNGX icon
7
Tango Therapeutics
TNGX
$4.43B
$6.65M 0.56%
4,854,443
– –
XLO icon
8
Xilio Therapeutics
XLO
$59.9M
$6.6M 0.56%
650,389
– –
KLRS
9
Kalaris Therapeutics
KLRS
$83.5M
$5.81M 0.49%
723,273
– –
HOOK
10
DELISTED
HOOKIPA Pharma
HOOK
$2.03M 0.17%
1,875,945
– –
ALLO icon
11
Allogene Therapeutics
ALLO
$649M
$1.69M 0.14%
1,156,689
– –
CYPH
12
Cypherpunk Technologies Inc
CYPH
$62.9M
$1.62M 0.14%
5,319,148
– –
IMA
13
ImageneBio Inc
IMA
$63M
$1.48M 0.13%
96,595
-70,767
-42% -$1.22M
BRNS
14
Barinthus Biotherapeutics
BRNS
$22.8M
$360K 0.03%
369,855
-250,496
-40% -$257K
AGEN
15
Agenus
AGEN
$312M
– –
-231,663
Closed -$635K
KRON
16
DELISTED
Kronos Bio
KRON
– –
-188,567
Closed -$179K

Similar funds

BCM
Basswood Capital Management New York $2.12B AUM 19.53% 1-Year Est. Return
IVAV
Index Venture Associates VI St. Helier, Channel Islands, Jersey $2.11B AUM 13.76% 1-Year Est. Return
EF
Empirical Finance Havertown, Pennsylvania $2.13B AUM 29.56% 1-Year Est. Return
HJGA
Hardman Johnston Global Advisors Stamford, Connecticut $2.1B AUM 41.89% 1-Year Est. Return
CF
Centaurus Financial Anaheim, California $2.1B AUM 21.28% 1-Year Est. Return
BWC
Blue Whale Capital London, United Kingdom $2.1B AUM 97.03% 1-Year Est. Return
SFS
Strategic Financial Services Utica, New York $2.1B AUM 19.14% 1-Year Est. Return
AAP
Aristotle Atlantic Partners Sarasota, Florida $2.14B AUM 37.01% 1-Year Est. Return

Gilead Sciences's Q1 2025 Portfolio in Review

As of Q1 2025, Gilead Sciences held 16 positions worth $1.18B, down 24% from $1.55B the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Gilead Sciences's Q1 2025 filing shows 1 increased, 2 reduced and 2 closed positions. The largest sale was ImageneBio Inc, an estimated $1.22M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 99% a quarter earlier, followed by Financials.

  • Gilead Sciences added most to Arcus Biosciences in Q1 2025, an estimated $15.8M increase.
  • Gilead Sciences's biggest Q1 2025 reduction was ImageneBio Inc, cutting an estimated $1.22M.
  • Gilead Sciences fully exited Agenus in Q1 2025, selling an estimated $635K.
  • Gilead Sciences's ten largest holdings make up 100% of its $1.18B portfolio in Q1 2025.
  • Gilead Sciences opened 0 new positions and closed 2 in Q1 2025.
  • Gilead Sciences's portfolio value fell 24% quarter-over-quarter to $1.18B.

Based on Gilead Sciences's 13F filing for Q1 2025, filed 13 May 2025.